

Topic

- Cases and Deaths
- Case Rates
- Death Rates
- Syndromes
- Serogroups
- Surveillance Report

Year

2024

*Dataset version: Feb 2026
Final run: Mar 23, 2026*

Note: Click [here](#) to access and download Surveillance Reports.

Group A *Streptococcus* (GAS) Group B *Streptococcus* (GBS) *Haemophilus influenzae* (HFlu) ***Neisseria meningitidis* (NMen)** *Streptococcus pneumoniae* (SPN) Bact Facts

**Active Bacterial Core Surveillance (ABCs) Report
Emerging Infections Program Network
Neisseria meningitidis, 2024**

ABCs Areas: California (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia; Maryland; Minnesota; New Mexico; New York (15 county Rochester and Albany areas); Oregon; Tennessee (20 counties)

ABCs Population: The surveillance areas represent 46,473,142 persons. Source: Census Bureau's Vintage 2024 population estimates.

ABCs Case Definition: Disease is defined as isolation of *N. meningitidis* from a normally sterile site or detection of pathogen-specific nucleic acid in a specimen obtained from a normally sterile body site, using a validated molecular test in a resident of one of the surveillance areas.

ABCs Methodology: ABCs personnel routinely contacted microbiology laboratories serving acute care hospitals to identify cases. Standardized case report forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case. Serogrouping of meningococcal isolates was done at CDC and state laboratories. Regular laboratory audits assessed completeness of active surveillance and detected additional cases. Disease rates were calculated using population estimates from the Vintage 2024 file. For national estimates of cases and deaths, race- and age-specific rates of disease were applied from the aggregate surveillance area to the age and racial distribution of the U.S. population. Cases with missing data, excluding ethnicity, were multiply imputed using sequential regression imputation methods.†

ABCs Profiles

Race	No.	Rate*
Black	30	0.35
White	41	0.13
Other	10	0.18
Total	81	0.17

*Per 100,000 population for ABCs areas

Age (years)	B		C		Y		Other†	
	No.	Rate*	No.	Rate*	No.	Rate*	No.	Rate*
<1	0	0.00	1	0.21	0	0.00	0	0.00
1	0	0.00	0	0.00	1	0.20	0	0.00
2-4	0	0.00	0	0.00	1	0.07	0	0.00
5-17	0	0.00	0	0.00	0	0.00	0	0.00
18-34	1	0.01	1	0.01	1	0.01	4	0.04
35-49	1	0.01	2	0.02	19	0.20	5	0.05
50-64	3	0.04	1	0.01	16	0.19	1	0.01
65-74	2	0.04	1	0.02	6	0.13	1	0.02
75-84	0	0.00	1	0.04	8	0.31	2	0.08
≥85	0	0.00	0	0.00	1	0.12	0	0.00
Total	7	0.02	7	0.02	53	0.11	13	0.03

*Per 100,000 population for ABCs areas
†Other includes serogroup W and non-groupables
‡Unknown serogroup (n=6) distributed amongst known.

Citation
Centers for Disease Control and Prevention. 2024. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, *Neisseria meningitidis*, 2024. www.cdc.gov/abcs/downloads/NMEN_Surveillance_Report_2024.pdf

Syndromes

Syndrome	Cases		Deaths	
	No.	%*	No.	Rate†
Meningitis	31	38.3	1	3.2
Bacteremia Without Focus	18	22.2	1	6.3

*Percent of cases
†Deaths per 100 cases with known outcome

Rates of Meningococcal Disease in Adolescents and Young Adults

Serogroup	C/Y/W		Overall	
	Age (years)	No.	Rate*	No.
11-17	0	0.00	0	0.00
	0	0.00	1	0.03

*Per 100,000 population for ABCs areas

National Estimates of Invasive Disease
Total Cases: 590 (0.2/100,000 population)
Deaths: 60 (0.02/100,000 population)
In 2024, 522 cases of meningococcal disease (confirmed and probable) were reported to the NNDSS, resulting in an incidence of 0.15/100,000 population. The 2024 NNDSS data are provisional. For more information on national incidence, view our Enhanced Meningococcal Disease Surveillance Report at <https://www.cdc.gov/meningococcal/php/surveillance/index.html>.

† Surveillance Note
Missing race (n=17) data were multiply imputed using sequential regression imputation methods.